Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1

Interventions

Cyclophosphamide 10Magnetic Resonance Spectroscopy 8Temozolomide 6Biopsy 6dinutuximab 5X-Rays 5Topotecan 5Specimen Handling 5Phantoms, Imaging 5Nuclear Medicine Department, Hospital 5Irinotecan 5Etoposide 3Colony-Stimulating Factors 3ulixertinib 2tipifarnib 2selpercatinib 2sargramostim 2pembrolizumab 2palbociclib 2naxitamab 2larotrectinib 2ivosidenib 2fludarabine phosphate 2fludarabine 2etoposide phosphate 2erdafitinib 2ensartinib 2Lenalidomide 2Isotretinoin 2Granulocyte-Macrophage Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neuroblastoma × IL32 protein, human × Clear all
NCT02573896 2026-03-23

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Active not recruiting
13 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡